Cryo-Cell International Reports Q2 Fiscal 2026 Revenue Decline to $7.8 Million

Cryo-Cell International, Inc. reported its financial results for the second quarter of fiscal 2026, revealing a total revenue of $7.8 million for the three months ended May 31, 2026, a decrease of 2% from $7.9 million in the same period last year. For the six months ended May 31, 2026, revenue totaled $15.5 million, down from $15.9 million in the prior year. The decline in revenue was primarily attributed to a 14% decrease in the number of new domestic cord blood specimens processed, despite a 3% increase in recurring annual storage fee revenue. Processing and storage fees accounted for the majority of revenue, totaling $15.4 million for the six-month period, compared to $15.7 million in the previous year.

The company's cost of sales also decreased, falling 13% to $3.3 million for the six months ended May 31, 2026, down from $3.8 million in the same period last year. This reduction was attributed to process enhancements and improved quality systems in the processing of cord blood specimens. However, selling, general, and administrative expenses rose by 8% to $9.6 million, reflecting increased marketing and personnel costs. The company reported a net income of $601,694 for the six months ended May 31, 2026, compared to $638,640 in the prior year, with net income per share remaining stable at $0.07.

In terms of operational metrics, Cryo-Cell's total assets decreased to $60.7 million as of May 31, 2026, from $61.7 million at the end of the previous fiscal year. The company reported a cash and cash equivalents balance of $507,302, an increase from $319,031 at the end of November 2025. The company’s accounts receivable also saw a slight increase, totaling $6.9 million, compared to $6.8 million in the prior period. The company continues to maintain a strong focus on its core business of cellular processing and cryogenic storage, which remains its primary revenue driver.

Strategically, Cryo-Cell has been navigating challenges related to its Patent and Technology License Agreement with Duke University, which has been a significant focus for the company. The company filed a demand for arbitration against Duke, alleging fraudulent inducement and breach of contract, which has led to a pause in its plans to expand into new business units related to clinical services and biopharmaceutical manufacturing. The outcome of this arbitration could significantly impact the company's future operations and financial performance.

Looking ahead, Cryo-Cell anticipates that its cash reserves, marketable securities, and cash flows from operations will be sufficient to meet its known cash needs for at least the next 12 months. However, the company acknowledges that its future performance will depend on increasing revenues from its core services and managing expenses effectively. The ongoing dispute with Duke University remains a critical factor that could influence the company's strategic direction and financial stability in the coming periods.